Analyst firms · Morgan Stanley · GSK

Morgan Stanley GSK price target and rating history

GSK plc (GSK) · Health Care

Morgan Stanley rates GSK plc (GSK) Equal-Weight with a $44 price target, as of its latest action on Feb 12, 2025. It has published 3 rating actions on GSK since August 2022, including 0 upgrades and 0 downgrades.

Current rating
Equal-Weight
Price target
$44
Median target, all firms
Too few
Actions on GSK
3

Every Morgan Stanley rating on GSK

How other firms rate GSK

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
JefferiesHold$55.90Oct 29, 2026
Wolfe ResearchOutperform$70Oct 9, 2026
BerenbergBuySep 15, 2026
RBC Capital MarketsSector PerformSep 9, 2026
CitigroupNeutralJul 24, 2026
HSBCHoldJul 6, 2026
BarclaysUnderweightJan 6, 2026
BofA SecuritiesNeutralNov 25, 2025

Questions about Morgan Stanley and GSK

What is Morgan Stanley's price target for GSK?
Morgan Stanley's latest stated price target for GSK plc (GSK) is $44, from its action on Jan 23, 2024.
What is Morgan Stanley's rating on GSK?
Morgan Stanley rates GSK Equal-Weight, a neutral rating, as of Feb 12, 2025.
When did Morgan Stanley last change its view on GSK?
On Feb 12, 2025, Morgan Stanley starts coverage at Equal-Weight.

More GSK rating histories

All Morgan Stanley ratingsGSK news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.